How to prepare carcinogenicity reports and supporting assessments

What should a carcinogenicity study report make traceable?

Connect the actual model, treatment and observation period, animal disposition, pathology and analysis to the study conclusions. Keep survival context visible when interpreting tumor findings. Distinguish a completed study report from an integrated weight-of-evidence assessment or a proposal about whether further studies add value.

Before you begin

Writing and organizing available carcinogenicity evidence. This page does not decide whether a two-year rat study is needed or whether an alternative is acceptable.

What you will prepare: A reviewable report package with coherent pathology, exposure, analysis and program-assessment cross-references.

Distinguish reports from the program assessment

The hierarchy separates long-term reports (4.2.3.4.1), short- or medium-term reports (4.2.3.4.2), and other studies (4.2.3.4.3). Identify the purpose and actual design before assigning a report. Supporting mechanistic evidence and an integrated weight-of-evidence assessment have different roles from a completed bioassay.

The final November 2022 S1B(R1) addendum introduces an integrative approach to assessing whether a two-year rat study adds value. It is not a universal exemption, and its scope directs biotechnology-derived products to S6(R1). A writer should document the program's actual rationale and agency interactions, not turn a general guidance option into an assumed agreement for this product.

Make long-term results interpretable alongside survival

For a long-term report, collect the protocol and amendments, animal disposition, actual treatment duration, dosing and exposure records, pathology outputs, statistical analysis and any pathology review documentation. Reconcile the counts in the disposition record with the populations used for incidence analyses.

Describe tumors and relevant non-neoplastic findings with their anatomical and diagnostic context. Ask the responsible pathologist and statistician to explain the interpretation of survival differences, early deaths and the selected analysis. A simple tumor percentage does not tell the whole story when observation time differs substantially between groups. Use the documented method and qualified interpretation rather than inventing an adjustment during writing.

Explain model-specific and supporting evidence

For a short- or medium-term report, explain the model, what it can evaluate, treatment and observation intervals, endpoint ascertainment and controls. Keep the model's limitations visible when discussing the human-risk question. “Shorter” does not mean the report can omit the reasoning needed to interpret its findings.

For other carcinogenicity studies, state the unresolved question the work addresses and connect the measured evidence to that question. A mechanistic result may help explain a finding without independently proving the absence of human risk. If an assessment cites general-toxicity, genetic-toxicology or pharmacology evidence, identify the original report locations and versions; do not re-author their conclusions to make the argument appear more consistent.

Review a conflict between the assessment and final pathology

Fictional example: the weight-of-evidence assessment describes an absence of a particular lesion, while a final pathology amendment reports it in one treatment group. The reviewer should determine whether the assessment used an earlier report and ask the scientific owner to reconsider the affected argument.

Update the traceable assessment and related summaries through the controlled review process. Retain uncertainty if the new observation's significance is unresolved. The correction is complete when the package identifies the final evidence and its implications consistently, not merely when the conflicting sentence is deleted.

Link the study result to the assessment argument

Build an argument-to-evidence table for the discussion and any later weight-of-evidence assessment. This editorial table does not replace the applicable scientific framework or agency interaction.

Require the evidence reference before polishing the argument. If the supporting report is not final, preserve that status in the assessment's review record. Do not remove a limitation merely because a more definite conclusion would make the narrative shorter.

Comparison exercise: two groups show the same crude percentage for a lesion, but their survival experience differs. The writer should not conclude that the finding is equivalent or select an adjustment independently. Obtain the statistician's documented analysis and interpretation, then explain its conclusion alongside the pathology assessment.

Trace scientific dependencies into the genotoxicity reports and general toxicity reports where the argument actually uses them. Carry the final evidence relationships into the nonclinical overview, including unresolved human relevance.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides